MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

154.03
+4.81
+3.22%
After Hours: 154.03 0 0.00% 16:00 09/25 EDT
OPEN
147.62
PREV CLOSE
149.22
HIGH
154.23
LOW
146.84
VOLUME
258.73K
TURNOVER
--
52 WEEK HIGH
158.93
52 WEEK LOW
90.06
MARKET CAP
8.14B
P/E (TTM)
-24.9090
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Biotech stock reversed course last week, dragged lower by the broader market weakness.
Benzinga · 16h ago
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 2d ago
Ascendis Pharma files for late-stage study with TransCon in Japan
Ascendis Pharma (ASND) has filed a Clinical Trial Notification with the Pharmaceuticals and Medical Devices Agency ((PMDA)) in Japan seeking approval to initiate Phase 3 riGHt Trial of TransCon hGH (lonapegsomatropin), a
Seekingalpha · 3d ago
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan
COPENHAGEN, Denmark, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it has filed a Clinical Trial Notification (CTN) with the Pharmaceuticals and
GlobeNewswire · 3d ago
Ascendis Pharma A/S Announces Support for Childrens Growth Awareness Week and Day 2020
– Introduces Together4Growth to increase awareness of children’s growth disorders, including a four-question Growth Quiz to help parents identify signs and symptoms –       – Public encouraged to visit www.together4growth.com and share their growth disorder stories using Together4Growth –COPENHAGEN,
GlobeNewswire · 09/15 22:45
Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find articles about an
Insider Monkey · 09/15 13:30
Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
COPENHAGEN, Denmark, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the 18th Annual Morgan Stanley Virtual Global
GlobeNewswire · 09/11 11:05
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting
COPENHAGEN, Denmark, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced three presentations for its TransCon PTH program for hypoparathyroidism (HP) at the
GlobeNewswire · 09/10 11:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASND. Analyze the recent business situations of Ascendis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASND stock price target is 174.72 with a high estimate of 208.73 and a low estimate of 151.63.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 59.26M
% Owned: 112.15%
Shares Outstanding: 52.84M
TypeInstitutionsShares
Increased
66
3.19M
New
50
253.76K
Decreased
41
3.17M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Senior Vice President/General Counsel/Director
Michael Wolff Jensen
Chairman/Senior Vice President/Director
Michael Jensen
President/Chief Executive Officer/Executive Director
Jan Moeller Mikkelsen
Chief Financial Officer/Senior Vice President/IR Contact Officer
Scott Smith
Senior Vice President/Chief Administrative Officer
Lotte Soenderbjerg
Senior Vice President
Vibeke Breinholt
Senior Vice President
Flemming Jensen
Senior Vice President
Thomas Larson
Senior Vice President
Jens Okkels
Senior Vice President
Dana Pizzuti
Senior Vice President
Juha Punnonen
Senior Vice President
Kennett Sprogoee
Chief Accounting Officer/Vice President - Finance
Peter Rasmussen
Independent Director
Lisa Bright
Independent Director
Albert Cha
Independent Director
James Healy
Independent Director
Lars Holtug
Independent Director
Birgitte Volck
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ASND
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Ascendis Pharma A/S stock information, including NASDAQ:ASND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASND stock methods without spending real money on the virtual paper trading platform.